Print

Merrimack Pharmaceuticals Inc. Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy  
12/20/2012 9:19:42 AM

CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study is designed to identify predictive biomarkers associated with the novel compound MM-398 in advanced colorectal, lung and triple-negative breast cancers. Specifically, it aims to establish the feasibility of collecting specialized magnetic resonance-based images (MRI) and tissue-based biomarkers for the purpose of estimating drug delivery to the tumor and patient response to MM-398.
//-->